{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:20:09Z","timestamp":1789514409041,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.hoc.2019.08.020","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:22:13Z","timestamp":1572254533000},"page":"127-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Hematologic Malignancies"],"prefix":"10.1016","volume":"34","author":[{"given":"Yolanda D.","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2019.08.020_bib1","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.08.020_bib3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib4","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2017.10.015","article-title":"Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F Intergroup Randomized Trial","volume":"100","author":"Thomas","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib5","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.08.020_bib6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2018-99-114519","article-title":"PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group","volume":"132","author":"Fuchs","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.08.020_bib8","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.hoc.2019.08.020_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib10","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V128.22.923.923","article-title":"BEACOPP-escalated followed by radiotherapy of initial bulk or residual disease in advanced stage Hodgkin lymphoma: long-term follow up of the HD9 and HD12 trials of the German Hodgkin Study Group","volume":"128","author":"Kreissl","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.08.020_bib12","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2019.08.020_bib13","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.08.020_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/bjh.12997","article-title":"Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG)","volume":"167","author":"Hartmann","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2019.08.020_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2015.02.001","article-title":"Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era","volume":"92","author":"King","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib17","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3324\/haematol.2015.133025","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study","volume":"100","author":"Lazarovici","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2019.08.020_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib19","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.2004.06.088","article-title":"Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484","volume":"22","author":"Horning","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib20","first-page":"93a","article-title":"Chemotherapy alone with the ACVBP regimen is superior to three cycles of CHOP plus radiotherapy for treatment of low risk localized aggressive lymphoma: the LNH93-1 GELA study","volume":"100","author":"Reyes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.08.020_bib21","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.2006.07.0722","article-title":"CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"25","author":"Bonnet","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2019.08.020_bib23","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1200\/JCO.2015.65.4582","article-title":"Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736","volume":"34","author":"Stephens","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.adro.2017.04.004","article-title":"Diffuse large B-cell lymphoma in very elderly patients over 80 years old: incorporating consolidative radiation therapy into management decisions","volume":"2","author":"Pinnix","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3109\/10428194.2014.930853","article-title":"Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients","volume":"56","author":"Odejide","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2019.08.020_bib26","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1200\/JCO.2012.48.0467","article-title":"Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement","volume":"31","author":"Held","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","article-title":"Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma","volume":"32","author":"Held","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","article-title":"Radiotherapy to bulky and extralymphatic disease in combination with 6\u00d7R-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2\u00d72 randomized UNFOLDER trial of the DSHNHL\/GLA","volume":"36","author":"Pfreundschuh","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1182\/blood-2017-07-793984","article-title":"R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma","volume":"131","author":"Lamy","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.08.020_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib31","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.26687","article-title":"Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy","volume":"118","author":"Campbell","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2019.08.020_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2013.07.013","article-title":"Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma","volume":"109","author":"Verhappen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2019.08.020_bib36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","article-title":"Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG","volume":"104","author":"Binkley","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib37","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.25117","article-title":"Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy","volume":"116","author":"Campbell","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2019.08.020_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ijrobp.2015.12.019","article-title":"Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study","volume":"94","author":"Ruella","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"29","key":"10.1016\/j.hoc.2019.08.020_bib39","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","article-title":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","volume":"36","author":"MacManus","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib40","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3109\/10428190903186510","article-title":"Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas","volume":"50","author":"Martin","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2019.08.020_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2900120102","article-title":"Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas","volume":"12","author":"Ganem","year":"1994","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","article-title":"A\u00a0high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment","volume":"51","author":"Girinsky","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib43","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0167-8140(96)01854-3","article-title":"Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma","volume":"42","author":"Sawyer","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib45","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/annonc\/mdn529","article-title":"Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma","volume":"19","author":"Luthy","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","article-title":"Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure","volume":"86","author":"Russo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib47","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4\u00a0Gy versus 24\u00a0Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib48","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.1998.16.5.1916","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone","volume":"16","author":"Schechter","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2019.08.020_bib49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2019.02.002","article-title":"Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"104","author":"Pinnix","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib50","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","article-title":"Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant","volume":"84","author":"Goda","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2014.01.056","article-title":"Survival and neurocognitive outcomes after cranial or craniospinal irradiation plus total-body irradiation before stem cell transplantation in pediatric leukemia patients with central nervous system involvement","volume":"89","author":"Hiniker","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2018.05.067","article-title":"Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Pinnix","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib53","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","article-title":"How I treat extramedullary acute myeloid leukemia","volume":"118","author":"Bakst","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.08.020_bib54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ijrobp.2018.05.045","article-title":"Use of radiation in extramedullary leukemia\/chloroma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Bakst","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib55","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2018.05.009","article-title":"Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"101","author":"Tsang","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/019459989310900517","article-title":"Extramedullary plasmacytomas of the head and neck","volume":"109","author":"Wax","year":"1993","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.hoc.2019.08.020_bib57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0167-8140(99)00114-0","article-title":"Clinical course of solitary extramedullary plasmacytoma","volume":"52","author":"Liebross","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib58","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1259\/bjr\/54563070","article-title":"Definitive radiotherapy for extramedullary plasmacytomas of the head and neck","volume":"76","author":"Michalaki","year":"2003","journal-title":"Br J Radiol"},{"key":"10.1016\/j.hoc.2019.08.020_bib59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/COC.0b013e31819cca18","article-title":"Solitary plasmacytoma","volume":"32","author":"Dagan","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib60","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijrobp.2005.06.039","article-title":"Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients","volume":"64","author":"Ozsahin","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib61","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fonc.2016.00176","article-title":"Effect of akimbo versus raised arm positioning on breast and cardiopulmonary dosimetry in pediatric Hodgkin lymphoma","volume":"6","author":"Denniston","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib64","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","article-title":"Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and\/or deep inspiration breath hold","volume":"125","author":"Rechner","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib66","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijrobp.2017.06.003","article-title":"Pencil beam algorithms are unsuitable for proton dose calculations in lung","volume":"99","author":"Taylor","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0360-3016(02)02754-2","article-title":"Relative biological effectiveness (RBE) values for proton beam therapy","volume":"53","author":"Paganetti","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1748-717X-7-186","article-title":"Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin\u2019s lymphoma: dosimetric comparison and clinical considerations","volume":"7","author":"Fiandra","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib69","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2019.08.020_bib70","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","article-title":"Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma","volume":"129","author":"Starke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.hoc.2019.08.020_bib71","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/j.ijrobp.2018.07.080","article-title":"Comparison of radiation techniques in lower mediastinal lymphoma","volume":"102","author":"Everett","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2019.08.020_bib72","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2019.08.020_bib73","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.prro.2017.05.002","article-title":"Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: effectiveness and toxicity after photon or proton treatment","volume":"7","author":"Gunther","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2019.08.020_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819301133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858819301133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:12:39Z","timestamp":1760184759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858819301133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0889858819301133"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2019.08.020","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2019.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}